Dr. Galsky discusses combo of nivolumab plus trastuzumab deruxtecan in urothelial carcinoma
Matthew Galsky, MD, discusses study on the combination of nivolumab plus trastuzumab deruxtecan in urothelial carcinoma.
![New York skyscrapers](/files/MSHealth/Assets/Global/Newsroom/2021/ISMMS-Spotlight-Placeholder-2col-770x420-3.jpg)
Press Release
Immunotherapy After Bladder Cancer Surgery Shows Excellent Cancer-free Survival Rates
May 14, 2022 View All Press ReleasesPress Release
"Dr. Galsky Discusses Combination Immunotherapy In Bladder Cancer"
Jun 29, 2018 View All Press Releases